Alnylam Pharmaceuticals (ALNY) PT Raised to $508 at Stifel on Vutrisiran Success
Tweet Send to a Friend
Stifel analyst Paul Matteis raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $508.00 (from $495.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
